COCP Share Price | Cocrystal Pharma, Inc. Stock Analysis & Recommendation

Q: What does Cocrystal Pharma, Inc. do?

Overview: Cocrystal Pharma, Inc. is a clinical stage biotechnology company focused on discovering and developing novel antiviral therapeutics for serious and chronic viral diseases, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.Financial Snapshot: Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) Market cap: USD 16.18 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.92 Return on Equity: -216.99% Price to Book: 2.21Contact Details: Address: 19805 N Creek Pkwy, BOTHELL WA: 98011-8251 Tel: ['1 786 4591831', '1 833 4758247'] Fax: 1 302 6365454 Website: https://www.cocrystalpharma.com/

Q: Is Cocrystal Pharma, Inc. overvalued or undervalued?

As of 16 August 2021, Cocrystal Pharma, Inc. has moved from a valuation grade of risky to does not qualify. The company is currently considered overvalued given its negative financial performance and ratios. Key ratios include a Price to Book Value of 2.27, an EV to EBIT of -0.62, and a ROCE of -1606.10%. In comparison to its peers, Cocrystal Pharma's valuation metrics are significantly worse; for instance, Entera Bio Ltd. has a PE ratio of -9.4138 and an EV to EBITDA of -7.4257, indicating a more favorable position despite also being classified as does not qualify. Additionally, Context Therapeutics, Inc. shows a PE of -1.8736 and an EV to EBITDA of 1.1859. The company's stock has underperformed relative to the S&P 500, with a year-to-date return of -22.28% compared to the S&P 500's 2.44%, reinforcing the notion of overvaluation.

Q: Is Cocrystal Pharma, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Cocrystal Pharma, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a bearish MACD on the weekly timeframe, bearish Bollinger Bands across both weekly and monthly periods, and a bearish daily moving average. The KST indicates a mildly bearish trend on the weekly level, while the monthly shows a bearish stance. The Dow Theory reflects a mildly bearish trend on the weekly timeframe with no trend on the monthly. In terms of performance, the stock has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -37.13% compared to the S&P 500's 12.22%, and a 1-year return of -27.43% against the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

19.73 k

Shareholding (Dec 2025)

FII

0.11%

Held by 4 FIIs

DII

97.31%

Held by 3 DIIs

Promoter

0.02%

How big is Cocrystal Pharma, Inc.?

22-Jun-2025

As of Jun 18, Cocrystal Pharma, Inc. has a market capitalization of 16.18 million and reported net sales of 0.00 million with a net profit of -15.85 million over the last four quarters. Shareholder's funds are 9.52 million, and total assets amount to 13.46 million.

View full answer

What does Cocrystal Pharma, Inc. do?

22-Jun-2025

Cocrystal Pharma, Inc. is a clinical stage biotechnology company focused on developing antiviral therapeutics for serious viral diseases, with a market cap of $16.18 million and recent quarterly net profit of -$2 million.

View full answer

Who are in the management team of Cocrystal Pharma, Inc.?

22-Jun-2025

As of March 2022, the management team of Cocrystal Pharma, Inc. includes Dr. Gary Wilcox as Chairman and CEO, with Dr. Roger Kornberg, Dr. Phillip Frost, Dr. Anthony Japour, and Mr. Steven Rubin serving as directors.

View full answer

Is Cocrystal Pharma, Inc. overvalued or undervalued?

25-Jun-2025

As of August 16, 2021, Cocrystal Pharma, Inc. is considered overvalued with a valuation grade of "does not qualify" due to negative financial performance and ratios, including a Price to Book Value of 2.27 and a year-to-date return of -22.28%, significantly underperforming compared to its peers and the S&P 500.

View full answer

Is Cocrystal Pharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Cocrystal Pharma, Inc. is in a mildly bearish trend, indicated by bearish MACD and Bollinger Bands, and has underperformed the S&P 500 with a year-to-date return of -37.13% compared to the S&P 500's 12.22%.

View full answer

Compare Cocrystal Pharma, Inc. with Similar Stocks

Palatin Technologies, Inc.Entera Bio Ltd.Acasti Pharma, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 15 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.98

Return on Equity

-126.11%

Price to Book

1.94

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

43.31%

6 Months

26.36%

1 Year

-11.46%

2 Years

-11.46%

3 Years

-45.7%

4 Years

-72.78%

5 Years

-91.22%

Cocrystal Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

0.34%

EBIT to Interest (avg)

-11.78

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.92

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

5.84%

ROCE (avg)

ROE (avg)

0.95%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.94

EV to EBIT

-0.76

EV to EBITDA

-0.77

EV to Capital Employed

7.41

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-976.80%

ROE (Latest)

-126.11%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 3 Schemes (2.56%)

Foreign Institutions

Held by 4 Foreign Institutions (0.11%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 27.27% vs 26.67% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.40",
          "val2": "-3.20",
          "chgp": "25.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.40",
          "val2": "-3.30",
          "chgp": "27.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 49.71% vs 2.78% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.60",
          "val2": "-17.80",
          "chgp": "51.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.80",
          "val2": "-17.50",
          "chgp": "49.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.40

-3.20

25.00%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-2.40

-3.30

27.27%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 27.27% vs 26.67% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-8.60

-17.80

51.69%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-8.80

-17.50

49.71%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 49.71% vs 2.78% in Dec 2024

All Annual Results

Company CV

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc.

Pharmaceuticals & Biotechnology

Cocrystal Pharma, Inc., is a clinical stage biotechnology company. The Company focuses on discovering and developing novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. The Company focuses on developing and commercializing antiviral drug candidates for the treatment and prophylaxis of hepatitis C, influenza and norovirus. The Company uses computational methods to screen and design product candidates using its cocrystal structural information. The Company’s Hepatitis C Virus (HCV) Non-Nucleoside Polymerase Inhibitor CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a novel PB2 inhibitor for the treatment of influenza infection. The Company is also focused on identifying and developing nucleoside and non-nucleoside polymerase inhibitors for the treatment of Norovirus infections.

Company Coordinates

Company Details

19805 N Creek Pkwy , BOTHELL WA : 98011-8251

Tel: 1 786 45918311 833 4758247

https://www.cocrystalpharma.com/

Registrar Details